Interestingly, the 2014 ASCO treatment guidelines in HER2- breast cancer stated that creating evidence-based recommendations on treatments is challenging in patients with comorbidities, especially as evidence for drug efficacy is often from clinical trials, which generally exclude patients with comorbidities. Here, ERBB2 is linked to breast cancer.